Key clinical point: Erenumab was effective in achieving and sustaining the remission of medication overuse headache (MOH) in adults with chronic migraine (CM) and nonopioid MOH, with adverse events reflecting the known safety profile of erenumab.
Major findings: At 6 months, 140 mg erenumab was significantly more effective than placebo in achieving increased MOH remission (odds ratio [OR], 2.01; P < .001) and sustained MOH remission (OR, 2.63; P < .001). The most common treatment-emergent adverse events in both erunumab groups were constipation (15.2%) and COVID-19 (13.9%); no new adverse events were reported.
Study details: This phase 4 randomized controlled trial included 584 adults with CM and MOH in the nonopioid-treated cohort who did not respond to one or more preventive treatments. Participants were randomly assigned to receive monthly injections of erenumab (70 mg or 140 mg) or placebo for 24 weeks.
Disclosures: This study was funded by Amgen. Some authors declared being employees or stockholders of Amgen, and others declared having ties with various sources, including Amgen.
Source: Tepper SJ, Dodick DW, Lanteri-Minet M, et al. Efficacy and safety of erenumab for nonopioid medication overuse headache in chronic migraine: A phase 4, randomized, placebo-controlled trial. JAMA Neurol. Published online September 16, 2024. Source